Investigation Report on China's Repaglinide Market, 2018-2022

Publisher Name :
Date: 25-Oct-2018
No. of pages: 30

Description

Since the 1980s, China's economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China. And population aging and other factors sharply raise the incidence of type 2 diabetes. The number of type 2 diabetic patients in China surpassed 110 million at the end of 2017, and is growing by 1.5 million to 2 million every year.

Insulin secretagogues are mainly used to treat type 2 diabetes. Compared with sulfonylureas, insulin secretagogues have short-lasting effects and cause few hypoglycemia reactions.

Developed by Danish company Novo Nordisk and German company Boehringer Ingelheim, Repaglinide is a non-sulfonylurea-based insulin secretagogue used to control postprandial hyperglycemia. The drug was launched in the U.S. in Apr.1998. Entering China in 2000, Novo Nordisk's NovoNorm has few competitors. According to CRI's market research, by sales value, the market share of Novo Nordisk was about 80% in 2017, while the market share of Jiangsu Hansoh Pharmaceutical Co., Ltd., its major competitor, was less than 20%. But Novo Nordisk's market share is sliding because NovoNorm is more expensive than China-made generic drugs. In 2017, the sales value of Repaglinide was about CNY 272 million in China, representing a slow decline from 2013 to 2017. Considering good efficacy, reasonable prices, and the increasing number of type 2 diabetic patients, Repaglinide will still have certain growth potential in China in the next few years.

Topics Covered:


  • Situation of type 2 diabetes in China

  • Size of China's Repaglinide market

  • Major Repaglinide manufacturers in China

  • Competition on China's Repaglinide market

  • Retail prices of Repaglinide in China

  • Prospect of China's Repaglinide market from 2018 to 2022

Investigation Report on China's Repaglinide Market, 2018-2022

Table of Contents

1 Relevant Concepts of Repaglinide
1.1 Indications for Repaglinide
1.2 Development of Repaglinide in China
1.3 Governmental Approval of Repaglinide in China

2 Sales of Repaglinide in China, 2013-2017
2.1 Sales Value of Repaglinide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Repaglinide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Repaglinide by Dosage Form in China, 2013-2017

3 Major Repaglinide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Repaglinide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Novo Nordisk
3.2.1 Enterprise Profile
3.2.2 Sales of Novo Nordisk's Repaglinide in China
3.3 Jiangsu Hansoh Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in China
3.4 Tianjin Kangrui Pharmaceutical Co., Ltd.
3.5 Beijing Beilu Pharmaceutical Co., Ltd.
3.6 Beijing Winsunny Pharmaceutical Co., Ltd.

4 Prices of Repaglinide in China, 2017-2018
4.1 Novo Nordisk (NovoNorm)
4.2 Jiangsu Hansoh Pharmaceutical Co., Ltd. (Fulaidi)
4.3 Tianjin Kangrui Pharmaceutical Co., Ltd. (Tianhu)
4.4 Beijing Beilu Pharmaceutical Co., Ltd. (Ruiliean)
4.5 Beijing Winsunny Pharmaceutical Co., Ltd. (Wansheng Liping)

5 Prospect of China's Repaglinide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

List of Charts

Chart Sales Value of Repaglinide in China, 2013-2017
Chart Sales Value of Repaglinide in Parts of China, 2013-2017
Chart Sales Volume of Repaglinide in China, 2013-2017
Chart Sales Volume of Repaglinide in Parts of China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Volume of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Value of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Volume of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Beilu Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Winsunny Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Prices of Novo Nordisk's Repaglinide in Parts of China, 2017-2018
Chart Prices of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Prices of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Forecast on Sales Value of Repaglinide in China, 2018-2012

  • Global Metformin Hydrochloride Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......
  • Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......
  • Global Insulin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......
  • Global Insulin API Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116
    According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Glucagon Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
  • Global Acarbose Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
  • Global Insulin Glargine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77
    According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......
  • Global Liraglutide Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103
    According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......
  • Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs